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Introduction
Research on endogenous negative feedback or compensatory
mechanisms that serve to limit deleterious immune responses is
critical in the attempts to identify effective therapeutic targets 
[1, 2]. In recent years, vasoactive intestinal peptide (VIP) and VIP
receptors have shown their relevance as endogenous factors that
regulate inflammatory immune responses and immune tolerance
[3, 4]. The mechanisms involved include the deviation towards
Th2-driven inflammatory pathways, the specific recruitment and
development of Th2 cells and the peripheral expansion of regula-
tory T cells [3]. Endogenously, VIP is produced and secreted by
antigen-stimulated Th2 cells [5–7], resembling a cytokine-like act-
ing molecule [3, 4]. Interestingly, VIP knockout mice expressed an
asthmatic phenotype that is partially corrected after VIP treatment
[8]. This is agreement with current views of bronchial asthma as a
non-exclusive Th2 polarized immune response [9, 10]. VIP exerts
its immunological actions in a paracrine and/or autocrine manner,
through three different specific receptors: VIP type 1 receptor
(VPAC1 ), VPAC2 and PAC1 [11, 12]. Although seminal works in
the immune system described VIP as an anti-inflammatory agent,
acting as an endogenous macrophage-deactivating factor (see
reviews [3, 11, 13]), very little is known about the molecular reg-
ulation of VPAC receptors in macrophages. Delgado et al. [14]
have reported that in contrast to VPAC1 and PAC1 receptors – which
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Vasoactive intestinal peptide (VIP) was originally isolated as a vasodilator intestinal peptide, then as a neuropeptide. In the immune sys-
tem, VIP is described as an endogenous macrophage-deactivating factor. VIP exerts its immunological actions in a paracrine and/or
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ments downstream of MAPK kinase 1/2, PI3K/Akt, and particularly Jun-NH2 -terminal kinase signalling pathways.
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seem to be constitutively expressed in mice macrophages – VPAC2
is selectively expressed only after lipopolysaccharide (LPS) stimu-
lation. In lymphocytes, VPAC2 mRNA is an activation-induced
gene in several experimental conditions [15–18]. Despite the
inducible character of the VPAC2 gene, detailed data about the
promoter and regulatory elements scarcely exist and are limited to
the human genome [19, 20]. Very recently, Lutz and collaborators
have identified the core promoter region of the mouse VPAC2
receptor gene [21].
The present work represents the first study of the regulation of
VPAC2 mRNA by toll-like receptors (TLRs) in macrophages. TLRs
are the best-characterized signal generating receptors among the
pathogen-associated molecular patterns; they initiate key inflam-
matory responses and also shape the adaptive immunity [22, 23].
TLRs can be divided into two groups according to their cellular
localization: TLRs 1, 2, 4, 5, 6 are located mainly on the cell sur-
face and primarily recognize bacterial components, while TLRs 3,
7, 8 and 9 are mostly found in the endocytic compartments and
mainly recognize viral products [22, 23]. TLR-mediated innate
immune activation also induces several molecules shown to 
negatively regulate TLR signalling [24]. Although studies on VIP
immunoregulatory activities are of notable therapeutic interest [3],
the effects of TLRs on the induction of VPAC2 have not yet been
examined. Thus, the VPAC2 regulation by TLRs may play an
important role in positive and negative regulation of normal and
aberrant immune responses.
Our findings indicate that the VPAC2 gene is differentially
regulated by subsets of TLRs. Furthermore, VPAC2 mRNA is
tightly repressed by key protein kinase pathways: c-Jun-NH2 -
terminal kinase (JNK), mitogen-activated protein kinase (MAPK)
kinase 1/2 (MEK1/2), p38 MAPK and phosphatidylinositol-3
kinase (PI3K/Akt).
Materials and methods
Animals
Female C57BL6/JIco mice (4–8 weeks old) were maintained in the
Animal Breeding Center of the University of Seville. Experiments were
carried out under the supervision and guidelines of the Animal Welfare
Committee.
Cell culture and reagents
Raw 264.7 cells (ECACC, Porton Down, Wiltshire, UK) were grown in RPMI
1640 medium supplemented with 10% heat-inactivated foetal bovine
serum (BioWhitaker, Verviers, Belgium), 2 mM glutamine, 100 U/ml peni-
cillin and 100 g/ml streptomycin (Sigma, St. Louis, MO, USA). Peritoneal
macrophages were isolated and pooled after intraperitoneal injection of 
1 ml of 3% thioglycolate at day 5 (Fluka, Milwaukee, WI, USA). TLR ligands
were as follows: LPS (E. coli serotype 0127: B8, Sigma), oligodeoxynu-
cleotide containing unmethylated CpG motifs (CpG: CpG-DNA 1668: 5-
TCCATGACGTTCCTGATGCT-3, TIB MolBiol, Berlin, Germany), polyi-
nosinic: polycytidylic acid (poly I: C), flagellin, lipoteichoic acid (LTA), syn-
thetic bacterial lipopeptide Pam3 CSK4, synthetic lipoprotein derived from
Mycoplasma (FSL-1), peptidoglycan (PGN), imiquimod and ssRNA40 were
obtained from InvivoGen (San Diego, CA, USA). SB203580 (a p38 MAPK
inhibitor), SP600125 (a JNK inhibitor), PD98059 (a MEK1/2 inhibitor),
LY294002 (a PI3K/Akt inhibitor) were all from Sigma.
Cytokine assays
Supernatants from Raw 264.7 cells and thioglycolate-elicited peritoneal
macrophages were harvested 24 hrs after TLR stimulation. Interleukin 
6 (IL-6) ELISA determinations were carried out according to the manufac-
turer’s instructions (OptEIA Mouse IL-6 set, BD Pharmingen, San Diego,
CA, USA).
Quantitative real-time PCR (qPCR)
Raw 264.7 cells were seeded into 12-well plates in a final volume of 2 ml.
At 70–80% confluence, cells were stimulated with LPS (1 g/ml), CpG
(1 g/ml, CpG-DNA 1668), Poly (I: C) acid (50 g/ml,), LTA (10 g/ml),
Pam3 CSK4 (300 ng/ml), FSL-1 (1 g/ml), PGN (10 g/ml), imiquimod 
(10 g/ml) or ssRNA40 (0.25 g/ml). Peritoneal macrophages were
adherent-isolated by overnight culture into 12-well plates in 1.5 ml RPMI
1640. Then, non-adherent cells were removed and peritoneal macrophages
were treated as indicated above. Twenty-four hours later, RNA from cell
cultures was extracted using Tripure™ isolation reagent (Roche, Basel,
Switzerland) and qPCRs of VPAC2 , IL-6 or the housekeeping gene HPRT
were carried out. For qPCR determinations (MiniOpticon detector, BioRad,
Hercules, CA, USA), 1 g of RNA was reversely transcribed and genomic
DNA removed using QuantiTect Reverse Transcription Kit (Qiagen,
Valencia, CA, USA). One hundred nanograms of cDNA were amplified
using 12.5 l of 2 FastStart SYBR Green Master Mix (Roche), 200 nM of
each primer and H2 O up to 25 l. The PCR amplification scheme was: 
10 min. at 95C; followed by 50 cycles at 95C 15 sec., 65C 30 sec. and
30 sec. at 72C. HPRT (ID genebank accession number 15452) was used
as housekeeping gene (forward 5-GTAATGATCAGTCAACGGGGGAC-3,
reverse 5-CCAGCAAGCTTGCAACCTTAACCA-3 (174 bp in length span-
ning from nucleotide 464 to 638). The VPAC2 sequence (ID genebank
accession number 22355) was used to design the VPAC2 primers. The
oligonucleotides were as follow: forward 5-GGACAGCAACTCGCCTCTCT-3
(nt 825–844), reverse 5-CCCTGGAAGGAACCAACACATAAC-3
(nt 1129–1152) (328 bp in length). IL-6 primers (ID genebank accession
number 16193) were: forward 5-TTCCATCCAGTTGCCTTCTT-3, reverse 
5-ATTTCCACGATTTCCCAGAG-3 (170 bp in length spanning from
nucleotide 55 to 225). SYBR-Green I detection was followed by generation
of melting curves and visualization of the products to confirm specificity.
Quantitative PCR results were obtained using the Ct method [25]. The
induction of mRNA was calculated as 2Ct.
Statistical significance
For statistical evaluation, Mann-Whitney rank sum tests were performed to
differentiate between experimental groups.
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Results and discussion
The VPAC2 gene is constitutively expressed in both Raw 264.7
cells and peritoneal macrophages (Fig. 1). VPAC2 mRNA levels
were up-regulated upon LPS treatment, as previously reported by
Delgado and collaborators [14]. In our experimental setting, we
were able to detect a constitutive expression of VPAC2 mRNA in
resting macrophages while Delgado and collaborators [14] did not
detect it by conventional RT-PCR in resting Raw 264.7 cells. This
discrepancy could be due to differences in the sensitivity of the
systems used (conventional versus real time PCR) or the efficiency
of the primers used in each study. Besides, what is constitutive or
not relies on the experimental technique or reagents used in each
case. In this sense, we reproduced the responsive character of the
VPAC2 gene pioneered reported by Delgado and collaborators [14]
and this information about the inducible nature of the VPAC2 gene
is the relevant message in terms of biological interpretation.
LPS treatment caused about three-fold induction of VPAC2
mRNA levels in Raw 264.7 cells. Interestingly, PGN, a ligand for
TLR2, or ligands for TLR2/6 heterodimers such as LTA or the
lipopeptide FSL-1 – a synthetic analogue of mycoplasmal lipopro-
tein – were able to up-regulate VPAC2 gene expression in Raw
264.7 cells (Fig. 1A). In contrast, Raw 264.7 cells treated with
Pam3 CSK4 – a TLR2/1 ligand – did not modify the mRNA levels
of VPAC2 receptors (Fig. 1A). Therefore, VPAC2 gene expression
is regulated by components of gram-positive (TLR2 ligands) and
gram-negative bacteria (TLR4 ligands) cell walls. These data also
imply that different TLR-mediated signalling pathways may result
in the selective regulation of the VPAC2 gene.
VPAC2 is tightly regulated by TLR2- or TLR2/6-mediated
mechanisms. TLR2/1 heterodimers recognize triacyl lipopeptides
such as Pam3 CSK4, and TLR2/6 heterodimers recognize diacyl
lipopeptides. Findings of differential responses mediated by TLR1
are scarcely known. Recently, defects in TLR1 recognition have
been related to ineffective responses to lipoprotein antigens in
mice and human beings, providing a link between TLR1 and
acquired antibody responses [26]. The reason why VPAC2 up-
regulation is unresponsive to TLR2/1 stimulation is uncertain.
Synthetic bacterial lipopeptide Pam3CSK4, LTA and PGN have
been shown to exert a beneficial decrease in the Th2 phenotype in
allergic contexts [27–30], although there is no such a comprehen-
sive comparative analysis of the Th1 responses elicited by these
ligands. Although future studies should clarify the differences
observed with Pam3CSK4 regarding VPAC2 expression, they
might be related with specific features of the Th1-mediated
response by Pam3CSK4.
This is the first report of VPAC2 regulation by TLRs sensing
gram-positive bacteria. Recent studies support the concept that
chronic or recurrent microbial infections may contribute to ather-
osclerotic disease acting through TLR2 [31, 32]. The putative role
of VPAC2 in the modulation of innate responses affecting athero-
sclerosis is presently unknown and deserves further attention.
Optimal stimulation with CpG DNA motifs for TLR9, single
stranded RNA for TLR7, or poly (I: C) acid as a dsRNA synthetic
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Fig. 1 Differential TLRs regulation of VPAC2 mRNA in macrophages. (A)
Raw 264.7 cells were seeded into 12-well plates in a final volume of 2 ml.
At 70–80% confluence (750,000 cells/well), cells were stimulated with
LPS (1 g/ml), CpG (1 g/ml, CpG-DNA 1668: 5-TCCATGACGTTCCT-
GATGCT-3), Poly (I: C) acid (50 g/ml), LTA (10 g/ml), Pam3 CSK4
(300 ng/ml), FSL-1 (1 g/ml), PGN (10 g/ml), imiquimod (10 g/ml)
or ssRNA40 (0.25 g/ml). Twenty-four hours, RNA was extracted and
qPCR of VPAC2 was carried out. Results are the mean 	 S.D. of five
independent experiments performed in triplicate. (Inset) Samples from
qPCR samples on 1.7% agarose gel electrophoresis. Lanes showed the
DNA molecular size markers (M), reaction performed in the absence of
RT (–) and presence () of RT from resting Raw 264.7 RNA. (B) Female
C57BL6/JIco (n 
 20) peritoneal macrophages were isolated and pooled
after i.p. injection of thioglycolate medium at day 5 as described in the
‘Materials and methods’ section. For qPCR determinations of VPAC2
mRNA levels, cDNA (100 ng) was amplified as described in the ‘Materials
and methods’ section. Quantitative PCR results were obtained using the
Ct method [25]. The induction of mRNA was calculated as 2Ct
(normalized for HPRT as housekeeping gene). For statistical evaluation,
Mann-Whitney rank sum tests were performed. Asterisks indicate statistical
significance (*, P  0.05 versus control; **, P  0.01 versus control;
***, P  0.001 versus control).
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analogue for TLR3 did not modify VPAC2 mRNA levels (Fig. 1).
Therefore, VPAC2 gene is not affected by TLR-stimulation detect-
ing nucleic acids derived from viruses and bacteria. Imiquimod –
a specific TLR7 ligand – is an imidazoquinoline-like molecule.
Interestingly, imiquimod treatment of Raw 264.7 cells led to a
potent up-regulation of VPAC2 mRNA levels, causing 3.5 	 0.5
fold induction of VPAC2 mRNA levels in Raw 264.7 cells (Fig. 1A).
There is still a long way to go regarding the imiquimod molecular
mechanism of action and many questions remain unanswered.
This is the reason why ssRNA and imiquimod does not always
show similar effects. It has been shown that imiquimod has mech-
anisms of action that are TLR7-independent, suggesting a role for
adenosine receptors [33]. Topical imiquimod cream is an FDA-
approved treatment for superficial basal cell carcinomas [34].
Predominant among its actions is the induction, in transcutaneous
immunization protocols, of efficient Th1-antitumoral cellular
immunity [35, 36]. Fabricius and collaborators have reported an
inhibitory role for VIP in the production of interferon (IFN)- stim-
ulated by TLR9 ligands in human plasmacytoid cells [37].
Recently, a strong inhibitory effect after TLR7 stimulation on 
the IFN- production induced by TLR9 ligands has been shown
[38]. Even though the regulation of specific TLR7-mediated
responses by VIP has not been addressed, our results might 
provide grounds for a possible counter regulatory mechanism
mediated by VPAC2 receptors.
We extended our observations to peritoneal macrophages, a
more physiological context. Moreover, peritoneal macrophages,
contrary to Raw 264.7 cells, express TLR5 [39, 40]. TLR5 stimu-
lation is mediated through the interaction with gram-positive or
gram-negative bacterial flagellin [22, 24]. VPAC2 mRNA levels
were not affected by treatment with this bacterial constituent
(Fig. 1B). Using peritoneal macrophages, we confirmed the pat-
tern of VPAC2 gene regulation by TLR ligands (Fig. 1B). VPAC2 is
differentially up-regulated by ligands of TLR2, TLR2/6 and TLR4
receptors. The synthetic ligand for TLR7, imiquimod, also
increased the mRNA levels of the VPAC2 gene. Interestingly, the
increase in VPAC2 gene expression by LPS or imiquimod was
two-fold compared with that observed in Raw 264.7 cells, while
the induction mediated by TLR2 and TLR2/6 remained at the same
levels (Fig. 1B). To be certain that Raw 264.7 cells or peritoneal
© 2009 The Authors
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Fig. 2 IL-6 production after TLRs stimulation in macrophages. (A) Raw
264.7 cells were seeded into 12-well plates in a final volume of 2 ml. At
70–80% confluence, cells (750,000 cells/well) were stimulated with LPS
(1 g/ml), CpG (1 g/ml, CpG-DNA 1668: 5-TCCATGACGTTCCTGAT-
GCT-3), Poly (I: C) acid (50 g/ml), LTA (10 g/ml), Pam3 CSK4 
(300 ng/ml), FSL-1 (1 g/ml), PGN (10 g/ml), imiquimod (10 g/ml)
or ssRNA40 (0.25 g/ml). Twenty-four hours later, supernatants were
harvested for IL-6 ELISA determination. (B) mRNA IL-6 stimulation after
ssRNA treatment in Raw 264.7 cells. RNA was extracted for IL-6 gene
expression study after ssRNA treatment as described in the ‘Materials
and methods’ section. For qPCR determinations of IL-6 mRNA levels,
cDNA (100 ng) was amplified as described in the ‘Materials and meth-
ods’ section. Quantitative PCR results were obtained using the Ct
method [25]. The induction of mRNA was calculated as 2Ct. Results
are the mean 	 S.D. of five independent experiments performed in 
triplicate. (C) Female C57BL6/JIco (n 
 20) peritoneal macrophages
were isolated and pooled after intraperitoneal injection of 1 ml of 3%
thioglycolate at day 5 as described above. Afterwards, non-adherent cells
were removed and peritoneal macrophages were treated as indicated
above and 24 hrs later, supernatants were harvested for IL-6 ELISA
determination.
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macrophages have responded appropriately to the different TLR
ligands used, we determined IL-6 secretion or expression in both
Raw 264.7 cells and peritoneal macrophages as a well-recognized
marker of TLR-mediated activation [24] (Fig. 2).
TLRs have been shown to activate four major intracellular
kinase signalling pathways; p38 MAPK, JNK, MEK1/2 and
PI3K/Akt [24, 41, 42]. We studied the signalling pathways
involved in the induction of VPAC2 mRNA by TLR4, TLR2, TLR2/6
and TLR7 in Raw 264.7 macrophages. Previously, we checked
whether the specific inhibitors of the different kinase signalling
pathways or the TLR ligands used in the present study affected
cell viability at the concentration used herein (Fig. S1). No 
statistically significant differences were observed in terms of 
cell viability compared to the control experimental situation. The
proteasome inhibitor MG132 was used as a positive control 
for cytotoxicity.
The induction of VPAC2 expression triggered by LPS was com-
pletely abrogated by the blockade of the p38 MAPK-dependent
signalling pathway with the specific inhibitor SB203580 (Fig. 3)
[43, 44]. However, the up-regulation of VPAC2 mRNA levels
observed after treatment with PGN (TLR2), lipoteichoic acid
(TLR2/6) or imiquimod (TLR7) were not dependent on p38 MAPK
activity (Fig. 3). This is the first report that ascribes a signal trans-
duction cascade to the LPS induction of VPAC2 gene expression,
although we cannot exclude a partial indirect effect mediated by
pro-inflammatory cytokines triggered by LPS treatment as it has
been reported in the epidermal keratinocyte cell line DJM-1 for
VPAC1 [45]. Strikingly, SP600125 – a highly selective inhibitor of
JNK activity [46] – increased the mRNA levels of VPAC2 up 
to 12.5 	 1.4 fold compared to control values (Fig. 3). The co-
treatment of the different TLR ligands with the specific JNK
inhibitor always led to a dramatic increase in VPAC2 gene expres-
sion despite TLR2-, TLR2/6- or TLR7-mediated stimulation with-
out a synergistic effect (Fig. 3). Whether LPS triggers additional
counter mechanisms is presently unknown, but only the LPS co-
treatment with SP600125 abolished the effect that the JNK
inhibitor produced by itself in Raw 264.7 cells (Fig. 3). Addition of
the MEK1/2 signalling blocker [44, 47] PD98059 led to an increase
in VPAC2 mRNA levels which did not synergize with the TLR 
stimulation (Fig. 3). However, LPS-induced VPAC2 expression
was not reversed by blocking MEK1/2 activity, as was the case
when p38 MAPK activity was inhibited (Fig. 3), nor did LPS affect
the up-regulation of VPAC2 mRNA levels by MEK1/2 inhibition as
in the case of the inhibition of JNK (Fig. 3).
We blocked PI3K/Akt activity with LY294002 [48, 49]. PI3K/Akt
inhibition produced a 4.7 	 1.0 fold induction of VPAC2 mRNA in
Raw 264.7 macrophages (Fig. 3). PI3K/Akt inhibition did not
reverse the TLR-mediated up-regulation of VPAC2 mRNA.
Moreover, PI3K/Akt inhibition synergized with TLR ligands for
TLR7, but not for TLR4, TLR2 or TLR2/6 (Fig. 3). These data
strongly suggest a tightly repressed control of VPAC2 mRNA
induction by elements downstream of MEK1/2, PI3K/Akt and
especially JNK signalling pathways.
Recent studies have been highlighting that VIP decreases the
up-regulation of TLR2 and TLR4 in human monocytes [50], as
well as in lymphocytes, macrophages and dendritic cells after the
trinitrobenzene sulfonic acid induced colitis in mice [13, 51, 52].
Interestingly, VIP has also been reported to inhibit the LPS-
induced RNA expression of downstream adapters molecules
involved in TLR4 signalling pathways in fibroblast-like synovio-
cytes from patients with rheumatoid arthritis or osteoarthritis
[53]. We should notice the importance of understanding how the
TLR, associated kinases pathways and VIP receptors serve to
maintain the homeostasis and the integrity of the immune
response. In this sense, it has been shown very recently that VIP
suppresses TLR4 expression in macrophages via PI3K/Akt [54].
This is in agreement with increasing experimental evidence show-
ing that PI3K/Akt signalling pathway has a negative regulatory role
in inflammatory processes [55–57]. The VIP-mediated down-
 regulation of the pro-inflammatory response is partly explained by
activation of PKA and subsequent inhibition of p38 MAPK activity
and JNK activity in macrophages [1, 3]. Thus, it is conceivable to
propose that up-regulation of VPAC2 expression might be part of
a counter balance mechanism that allows a VIP-mediated anti-
inflammatory effect in situations that produce extensive inhibition
of the PI3K/Akt signalling pathway. In addition, the up-regulation
of VPAC2 expression could be part of the inflammatory deactivat-
ing cascade produced by VIP, partly due to its inhibitory effects on
p38 MAPK and JNK activities. Further experiments should address
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Fig. 3 Effects of protein kinase inhibitors on TLR-mediated VPAC2 
regulation in Raw 264.7 macrophages. Raw 264.7 cells were grown and
treated as above. Briefly, at 70–80% confluence, cells (750,000 cells/well)
were stimulated for 24 hrs with LPS (1 g/ml), LTA (10 g/ml), PGN 
(10 g/ml) or imiquimod (10 g/ml) after 30 min. pre-treatment in the
presence or absence of 10 M SB203580 (a p38 MAPK inhibitor), 25 M
SP600125 (a JNK inhibitor), 50 M PD98059 (a MEK1/2 inhibitor) and
10 M LY294002 (a PI3K/Akt inhibitor). Twenty-four hours later, RNA
was extracted and qPCR of VPAC2 was carried out according to the
‘Materials and methods’ section. Results are the mean 	 S.D. of three
independent experiments performed in triplicate. For statistical evalua-
tion, Mann-Whitney rank sum tests were performed. Asterisks indicate
statistical significance (*, P 0.05; **, P 0.01; ***, P 0.0001 versus
the experimental condition in the absence of inhibitor).
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protein expression levels of VPAC2. Unfortunately, although there
are no reliable/specific antibodies against VPAC2 receptors avail-
able so far, our data point out to new fine-tuned mechanisms of
control of VPAC2 receptors. Very recently, two findings highlight
the importance of the expression levels of VIP receptors in the
onset and evolution of autoimmune/inflammatory human
 diseases. Delgado and collaborators have shown a genetic associ-
ation involving VPAC1 receptor genetic polymorphisms and sus-
ceptibility of human rheumatoid arthritis, suggesting that an
impaired expression of VPAC1 could be related to the pathogene-
sis of rheumatoid arthritis [58]. Juarranz and collaborators have
shown that the inhibitory effects of VIP on fibroblast-like synovio-
cytes production of pro-inflammatory mediators were mimicked
by VPAC1 and VPAC2 specific agonists in these cells from patients
affected by osteoarthritis and rheumatoid arthritis, respectively,
with a predominant role for VPAC2 receptor in the latter [59].
Taken together, despite difficulties of homogenizing cell cultures
from synovial tissues from patients with different degrees of
rheumatoid arthritis and osteoarthritis, it is evident that VPAC
receptors regulate the threshold of autoreactivity in these diseases
where TLRs and their signalling pathways might have great poten-
tial as additional targets for new treatments. Last, we should not
rule out the possibility that the observed changes in the VPAC2
gene expression were based on post-transcriptional regulation of
its mRNA stability due to the inhibition of p38 MAPK, JNK or
PI3K/Akt signalling pathways as growing experimental evidence
has been showing [60–62].
Figure 4A summarizes our findings. Based on these results,
we postulate that up-regulation of VPAC2 by TLRs represents an
additional mechanism to ensure the modulator capabilities of
VIP, while at the same time a down-regulation of TLRs occurs. In
this sense, we used the Jaspar database (http: //jas-
par.genereg.net) to search for transcription factors possibly
involved in TLR-mediated signalling (Fig. 4B). The 3000
nucleotide long upstream region of the Mus musculus VPAC2
gene (ENSMUSG00000011171) was obtained from the Ensembl
database (http: //www.ensembl.org). We found putative binding
sites with a relative score threshold of 0.8 in the positive strand
for CREB1, Fos, GATA2, GATA 3 and IRF1/2 transcription factors.
It must be noted that most of the predictions will correspond to
sites bound in vitro, and therefore their functional significance
must be further analysed.
The present data shed light on how TLRs differentially decode
innate stimuli, not only to achieve protection but also to avoid
damage by uncontrolled inflammatory responses, in this case, by
means of VPAC2 receptor.
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Fig. 4 TLR-mediated control of VPAC2. (A) VPAC2 up-regulation by TLRs
represents an additional mechanism to ensure the modulator capabilities of
VIP while at the same time a down-regulation of TLRs occurs. (B)
Distribution of putative binding sites for transcription factors involved in TLR
signalling across the 3000 long upstream region of mouse VPAC2 gene.
Thicker lines correspond to more densely packed putative binding sites.
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Fig. S1 Effects of TLR ligands and protein kinase inhibitors on
cytotoxicity. Raw 264.7 cells were previously seeded into 96-well
plates to a final volume of 100 l. After 24-hrs treatment with pro-
tein kinase inhibitors, LDH release was calculated according to the
following equation: LDH release 
 [LDH supernatant/(LDH super-
natant  LDH cells)]*100. The proteasome inhibitor MG-132 
(6 M) was used as a positive control for cytotoxicity. Results are
the mean 	 S.D. of two independent experiments performed 
in duplicate.
This material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1582-
4934.2009.00662.x
(This link will take you to the article abstract).
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting information supplied by the authors.
Any queries (other than missing material) should be directed to the
corresponding author for the article.
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Appendix S1
Lactate dehydrogenase (LDH) release
LDH release from cells was measured to quantify the cytotoxicity by
using the Cytotoxicity Detection kit (Roche). Raw 264.7 cells were
previously seeded into 96-well plates in a final volume of 100 L.
After treatment, 100 L of the supernatants and 100 L of 1% Triton
X100-lysed cells were assayed for LDH content under each experi-
mental condition. LDH determinations were carried out according to
the manufacturer’s guidelines. LDH release was calculated according
to the following formula: LDH release 
 [LDH supernatant/(LDH
supernatant  LDH cells)]*100. The proteasome inhibitor MG-132
(Sigma) was used as a positive control for cytotoxicity.
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